CTRI/2020/05/025475尚未招募3 期
HIGH DOSE CYTARABINE IN DAILY (1, 2, 3) VERSUS ALTERNATE DAY (1, 3, 5) SCHEDULE FOR CONSOLIDATION IN ACUTE MYELOID LEUKEMIA: A COMPARATIVE STUDY - HIDAC 123
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. De novo AML,
- •2. Secondary AML (sAML) with a preceding history MDS/MPN, and
- •3. Therapy-related AML (tAML)
排除标准
- •1. Acute promyelocytic leukemia
- •2. Concomitant renal (creatinine > 1.5 x upper normal serum level) or hepatic (bilirubin, AST or ALP > 2 x upper normal serum level) dysfunction
- •3. Cardiac dysfunction (NYHA III/IV),
- •4. Uncontrolled infectious disease,
- •5. Primary coagulation disturbance,
- •6. Performance status (Eastern Cooperative Oncology Group) > 2
- •7. Active concomitant malignant disease
研究者
相似试验
已完成
不适用
High-dose cytarabin versus low-dose cytarabin plus interferon-alpha-2a both followed by maintenance with interferon-alpha-2a in chronic myeloid leukemiaChronic myeloid leukemia (CML)Myeloid leukaemiaCancerISRCTN84226319Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)102
已完成
不适用
High-dose cytarabin versus low-dose cytarabin plus interferon-alpha-2a both followed by maintenance with interferon-alpha-2a in chronic myeloid leukemia.NL-OMON27157Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl102
招募中
不适用
Modified Low dose Cytarabine versus Hypomethylating agent in Elderly AML patients who are unfit for intensive chemotherapy: Randomized clinical studyDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001891The Catholic University of Korea, Seoul St. Mary's Hospital50
已完成
2 期
A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual diseaseCore binding factor acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000152628Australasian Leukaemia and Lymphoma Group53
已完成
3 期
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutatioC92.0Acute myeloblastic leukaemia [AML]DRKS00000783niversity of Ulm144